+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030- Product Image
Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030- Product Image
Sale

Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5264367
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antiviral Therapeutics Market grew from USD 75.53 billion in 2023 to USD 82.01 billion in 2024. It is expected to continue growing at a CAGR of 8.28%, reaching USD 131.82 billion by 2030.

The scope of antiviral therapeutics encompasses treatments designed to manage viral infections by inhibiting the virus's lifecycle, preventing its replication, or boosting the host’s immune response. These therapeutics are a necessity given the global burden of viral diseases such as HIV, hepatitis, influenza, and the recent attention spurred by COVID-19. Applications range from acute management of viral outbreaks to chronic condition maintenance and prophylaxis for at-risk populations. The end-use scope extends across hospitals, specialty clinics, pharmacies, and direct patient consumption, supported by advancements in personalized medicine.

Market growth is influenced by increasing prevalence of viral infections, technological advancements in drug development, and substantial investments in R&D. The pipeline continues to expand with promising drug candidates using novel mechanisms like CRISPR-based antivirals, further brightening market prospects. Opportunities abound in leveraging AI to refine drug discovery processes, and in strategic alliances for technology transfer and global distribution, given the geographical disparities in healthcare access. However, limitations include rigorous regulatory requirements which can delay market entry, high costs associated with drug development, and emerging viral resistance necessitating continuous innovation.

Challenges such as patent cliffs, lack of effective treatments for emerging viruses, and disparities in healthcare infrastructure in low-resource settings can impede growth. Yet, the sectors ripe for innovation include combination antiviral therapies, long-acting injectables, and the exploration of host-targeted antivirals which can reduce the occurrence of resistance. Insights reveal a competitive market driven by rapid innovation cycles and the necessity of adaptive regulatory pathways to accommodate novel treatments. For business growth, focus on collaborations with biotech firms, investment in genetic and cell-based therapeutic platforms, and expansion into underserved markets can be key. Overall, an agile approach to research and development alongside a robust intellectual property strategy will be crucial in navigating this dynamic market landscape.

Understanding Market Dynamics in the Antiviral Therapeutics Market

The Antiviral Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising Prevalence of Viral Diseases Including HIV and Hepatitis
    • Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
    • Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
  • Market Restraints
    • Relatively High Cost Associated with Antiviral Drug Treatment
  • Market Opportunities
    • Advancements in Molecular Biology Promoting Drug Development
    • Improved Testing and Analysis of Viral Infections
  • Market Challenges
    • Adverse Effects of Antiviral Drugs

Exploring Porter’s Five Forces for the Antiviral Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Antiviral Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Antiviral Therapeutics Market

External macro-environmental factors deeply influence the performance of the Antiviral Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Antiviral Therapeutics Market

The Antiviral Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Antiviral Therapeutics Market

The Antiviral Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Eli Lilly and Company, Novartis AG, Johnson & Johnson Services Inc., Merck & Co., Inc., Syngene International Limited, Dr. Reddy’s Laboratories Ltd., Abbott Laboratories, Cocrystal Pharma, Inc., Atea Pharmaceuticals, Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Cipla Ltd., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Ltd., Pfizer Inc., Sanofi S.A., AbbVie Inc., Sun Pharmaceutical Industries Limited, Alkem Laboratories Limited, Gilead Sciences, Inc., Hetero Labs Limited, Viatris Inc., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Aurobindo Pharma Limited, Venatorx Pharmaceuticals, Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug
    • Hepatitis Antiviral Drug
    • Herpes Antiviral Drug
    • HIV Antiviral Drug
    • Influenza Antiviral Drug
  • Therapy
    • DNA Polymerase Inhibitors
      • Non-nucleosides
      • Purine Nucleoside Analogues
      • Pyrimidine Nucleoside Analogues
    • Neuraminidase Inhibitors
    • Protease Inhibitors
    • Reverse Transcriptase Inhibitors
      • Nonnucleoside RTIs
      • Nucleoside RTIs
      • Nucleotide RTIs
  • Distribution
    • Hospital Pharmacy
    • Independent Pharmacy & Drug Store
    • Online Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Viral Diseases Including HIV and Hepatitis
5.1.1.2. Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
5.1.1.3. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
5.1.2. Restraints
5.1.2.1. Relatively High Cost Associated with Antiviral Drug Treatment
5.1.3. Opportunities
5.1.3.1. Advancements in Molecular Biology Promoting Drug Development
5.1.3.2. Improved Testing and Analysis of Viral Infections
5.1.4. Challenges
5.1.4.1. Adverse Effects of Antiviral Drugs
5.2. Market Segmentation Analysis
5.2.1. Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
5.2.2. Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
5.2.3. Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
5.5. Client Customization
6. Antiviral Therapeutics Market, by Drug
6.1. Introduction
6.2. Hepatitis Antiviral Drug
6.3. Herpes Antiviral Drug
6.4. HIV Antiviral Drug
6.5. Influenza Antiviral Drug
7. Antiviral Therapeutics Market, by Therapy
7.1. Introduction
7.2. DNA Polymerase Inhibitors
7.2.1. Non-nucleosides
7.2.2. Purine Nucleoside Analogues
7.2.3. Pyrimidine Nucleoside Analogues
7.3. Neuraminidase Inhibitors
7.4. Protease Inhibitors
7.5. Reverse Transcriptase Inhibitors
7.5.1. Nonnucleoside RTIs
7.5.2. Nucleoside RTIs
7.5.3. Nucleotide RTIs
8. Antiviral Therapeutics Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Independent Pharmacy & Drug Store
8.4. Online Pharmacy
9. Americas Antiviral Therapeutics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antiviral Therapeutics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antiviral Therapeutics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
12.3.2. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults
12.3.3. Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
List of Figures
FIGURE 1. ANTIVIRAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTIVIRAL THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 45. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 73. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 74. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 77. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 78. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 79. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 81. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 88. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 89. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 90. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 118. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 119. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 144. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 145. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 146. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 163. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 164. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 165. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 166. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 167. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 179. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 180. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 183. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 184. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 185. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 187. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 238. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 239. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Antiviral Therapeutics market, which are profiled in this report, include:
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Syngene International Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Abbott Laboratories
  • Cocrystal Pharma, Inc.
  • Atea Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Company, Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Limited
  • Alkem Laboratories Limited
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Viatris Inc.
  • Takeda Pharmaceutical Company Limited
  • Themis Medicare Ltd.
  • Aurobindo Pharma Limited
  • Venatorx Pharmaceuticals, Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 82.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 131.82 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030 - Product Image

Oral Antiviral Market 2024 Edition: Market Size, Trends, Opportunities and Forecast by Drug Class, Indication, Distribution Channel, Region, By Country: 2020-2030

  • Report
  • 296 Pages
  • Global
From
Antivirals Drug - Global Strategic Business Report - Product Image

Antivirals Drug - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From
Antiviral Combination Therapy Global Market Report 2024 - Product Image

Antiviral Combination Therapy Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Antivirals Global Market Report 2024 - Product Image

Antivirals Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the Antivirals Market

The Antivirals market is a subset of the Infectious Diseases Drugs market, which includes drugs used to treat viral infections. Antivirals are used to treat a wide range of viral infections, including influenza, HIV, herpes, hepatitis, and other respiratory infections. Antivirals work by targeting the virus itself, preventing it from replicating and spreading throughout the body. They can also be used to reduce the severity of symptoms and shorten the duration of the illness. Antivirals are typically administered orally or intravenously, depending on the type of virus and the severity of the infection. In some cases, antivirals may be used in combination with other drugs to increase their effectiveness. Some of the major companies in the Antivirals market include Gilead Sciences, Merck & Co., Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb. These companies produce a variety of antiviral drugs, including those used to treat influenza, HIV, herpes, and hepatitis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.